Clinical trials: COX-2 Inhibitor
Major Depression
Cimicoxib for the Treatment of Major Depression (SECIM)
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression.
- Trial name
- NCT00510822
- Testing
- Cimicoxib
- Where
- 25 sites in Austria, Czechia and 1 more
- Volunteers
- 169 people
- Sponsor
- Affectis Pharmaceuticals AG
Pain
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic…
- Trial name
- NCT00333567
- Testing
- Lumiracoxib
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Novartis
Musculoskeletal Pain
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.
- Trial name
- NCT00170898
- Testing
- Lumiracoxib
- Where
- United Kingdom
- Volunteers
- 419 people
- Sponsor
- Novartis
Dental Pain, Surgery, Dental
Dental Pain (Following Third Molar Tooth Extraction) Study
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
- Trial name
- NCT00114049
- Testing
- GW406381
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Knee
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
This study was designed to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of osteoarthritis of the knee.
- Trial name
- NCT00120900
- Testing
- GW406381
- Where
- 19 sites in Denmark, Netherlands and 4 more
- Volunteers
- 1,340 people
- Sponsor
- GlaxoSmithKline
Contraception, Bleeding Pattern
Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women
In this study, the investigators propose to assess if a non-hormonal agent is absorbed by a local route (vaginal) and to observe the effect on follicular development.
- Trial name
- NCT01839643
- Testing
- Meloxicam 2.4 g, Meloxicam 3.0 g
- Where
- Chile
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Laboratorios Andromaco S.A.
Arthritis, Rheumatoid
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
- Trial name
- NCT00113308
- Testing
- GW406381
- Where
- 341 sites in United States, Argentina and 31 more
- Volunteers
- 2,208 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis
A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain
The purpose of this study is to investigate which pain mechanisms that can be affected by etoricoxib compared to placebo (inactive medication)in subjects with painful knee osteoarthritis af 4 weeks of treatment.
- Trial name
- NCT01619150
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- C4Pain
Knee Osteoarthritis
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)
- Trial name
- NCT00367315
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,684 people
- Sponsor
- Novartis
Acute Gouty Arthritis
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout.
- Trial name
- NCT00170781
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 234 people
- Sponsor
- Novartis